High-throughput protein and enzyme screening platform using bacterial secretion
Opera has developed a high-throughput protein screening tool using a bacterial host that fully secretes recombinant proteins and enzymes out of the cell in a single step. By secreting proteins at up to 90% purity, we are able to eliminate many of the purification steps needed to recover a protein from traditional E. coli expression but still preserves the speed and cost benefits of a bacterial host. The expression host is capable of secreting most heterologous proteins (88% success rate) that can be expressed in E. coli. The host has also shown increased expression titers for proteins that are normally toxic to cells. The same bacterial host can then be used for scale-up production for analytical characterization, activity testing, and commercial scale manufacturing.
We typically begin with fee-for-service protein and enzyme secretion evaluations and then expand into a high-throughput screening service. We are open to out licensing the technology and welcome partnerships.
About Opera Bioscience
Opera Bioscience is a biotechnology startup that has developed a proprietary bacterial protein secretion platform designed to make the manufacturing of recombinant proteins and growth factors more efficient, scalable, and cost-effective. By utilizing the type III secretion system of Salmonella enterica typhimurium, the platform enables the transport of proteins from the cytoplasm to the extracellular space in a single step. This approach simplifies the production process by eliminating the need for cell lysis and complex downstream purification steps, resulting in high-purity proteins. The technology is capable of producing soluble, active enzymes, antibody fragments, and antimicrobial peptides, positioning it for use across various applications including therapeutics, regenerative medicine, and the cultivated meat industry.
For customers and partners, Opera Bioscience addresses the high cost and complexity associated with traditional recombinant protein manufacturing. By offering a platform that reduces recovery costs and enables continuous manufacturing, the company aims to broaden access to essential biological materials for research, clinical applications, and sustainable consumer goods. Founded in 2021 and based in Evanston, Illinois, the company has received support from the National Science Foundation through multiple SBIR awards to optimize its strain development and scale its manufacturing processes. Opera continues to work on commercializing its platform, focusing on meeting industry demands for high-quality, affordable proteins and growth factors.
Inquire about this partnering listing
Looking for
Industry applications
delivered to your inbox.